Company Coeptis Therapeutics, Inc. OTC Markets
Equities
COEP
US19207C1045
Pharmaceuticals
Business Summary
Number of employees: 6
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 22-10-27 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 23-05-16 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 22-10-27 |
Colleen Delaney
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-08-29 |
Christine Sheehy
CMP | Compliance Officer | 57 | 22-10-27 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 22-10-27 | |
Director/Board Member | 55 | 22-10-27 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 22-10-27 |
Gene Salkind
BRD | Director/Board Member | 71 | 22-10-27 |
Chris Calise
BRD | Director/Board Member | 51 | 22-10-27 |
David Mehalick
CEO | Chief Executive Officer | 56 | 22-10-27 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 22-10-27 |
Director/Board Member | 56 | 22-10-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,089,917 | 24,345,215 ( 67.46 %) | 0 | 67.46 % |
Company contact information
Coeptis Therapeutics Holdings, Inc.
105 Bradford Road Suite 420
15090, Wexford
+
http://www.coeptistx.comSector
1st Jan change | Capi. | |
---|---|---|
+29.68% | 681B | |
+21.42% | 556B | |
-4.35% | 361B | |
+17.65% | 325B | |
+3.77% | 285B | |
+13.58% | 235B | |
+4.55% | 199B | |
-12.39% | 189B | |
-3.79% | 157B |